Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many content elements match the provided label excerpts (indication, mechanism via NMDA antagonist, acetylcholine/cholinesterase inhibitors, common adverse reactions, and some warnings). However, multiple statements cannot be fully supported by the supplied label text (notably treatment timing/“within a few weeks,” constipation, back pain, long-term duration phrasing, and some trial-effect claims), and some statements mix or generalize beyond what the excerpts explicitly state.
Category Scores
Accurate Statements
Memantine works by regulating the activity of glutamate, a neurotransmitter involved in learning and memory.
Supported indirectly by label mechanism statement that memantine is an NMDA receptor antagonist (NMDA is glutamate-related), but the label excerpt does not mention glutamate or learning/memory explicitly.
Memantine works through a different mechanism than cholinesterase inhibitors.
Supported: label describes memantine as an NMDA receptor antagonist (12.1/12.3) and donepezil as enhancing cholinergic function by increasing acetylcholine via reversible inhibition of acetylcholinesterase (12.1/12.3).
Cholinesterase inhibitors increase levels of acetylcholine, another neurotransmitter.
Supported: label states donepezil enhances cholinergic function by increasing concentration of acetylcholine through reversible inhibition of acetylcholinesterase (12.1/12.3).
Memantine targets the NMDA receptor.
Supported: label states memantine acts through its action as an NMDA receptor antagonist (12.1/12.3).
In Alzheimer's disease, glutamate can overstimulate the NMDA receptor.
Not explicitly supported in the provided label excerpts; mechanism excerpt identifies NMDA antagonism but does not describe glutamate overstimulation in Alzheimer's.
Memantine targets the NMDA receptor to help improve nerve cell function.
Partially supported: label postulates therapeutic effect via NMDA receptor antagonism (12.1/12.3) but excerpt does not explicitly state “improve nerve cell function.”
Memantine side effects can include dizziness.
Supported: most common adverse reactions with memantine hydrochloride extended-release include headache, diarrhea, and dizziness (6.1).
Memantine side effects can include headache.
Supported: most common adverse reactions with memantine hydrochloride extended-release include headache (6.1).
Some patients may experience improvements in cognitive function and daily living activities within a few weeks of starting memantine.
Not supported by the provided label excerpts; no specific “within a few weeks” timeframe is present in the supplied sections.
For some patients, it may take longer for memantine to show effects.
Not supported by the provided label excerpts; no timing language provided.
Memantine can cause vomiting.
Partially supported: label lists donepezil common adverse reactions including vomiting (6.1). Provided claim attributes to memantine; label excerpt does not explicitly say vomiting is a memantine adverse reaction.
Memantine can cause confusion.
Supported: donepezil postmarketing adverse reactions include confusion and hallucinations (6.2).
Memantine can cause hallucinations.
Supported: donepezil postmarketing adverse reactions include hallucinations (6.2).
Memantine side effects can include constipation.
Not supported by provided excerpts; constipation is not listed among common adverse reactions in provided sections.
Memantine can cause back pain.
Not supported by provided excerpts; back pain is not listed in the provided adverse reaction excerpts.
Memantine is usually prescribed for long-term management of moderate to severe Alzheimer's dementia.
Not explicitly supported in provided label excerpts; label excerpt does not use “long-term management” language or provide duration guidance.
The duration of memantine treatment is determined by a healthcare professional based on the patient's individual response and disease progression.
Not supported by the provided label excerpts; dosage and administration excerpts do not include individualized duration language.
Memantine is available as a generic medication.
Not supported in provided label excerpts; label excerpts do not address generic availability.
Multiple companies manufacture memantine.
Not supported in provided label excerpts; label excerpts do not address manufacturers.
The original patent for memantine hydrochloride expired, allowing generic versions to enter the market.
Not supported in provided label excerpts; label excerpts do not address patent status.
Other treatment options for Alzheimer's disease include cholinesterase inhibitors such as donepezil.
Partially supported: donepezil is an active ingredient in the labeled combination product, but the excerpt does not state it is an “other treatment option” for Alzheimer's beyond inclusion in the product.
In some cases, a combination of memantine and a cholinesterase inhibitor may be prescribed for patients with moderate to severe Alzheimer's disease.
Partially supported: the labeled product is memantine and donepezil hydrochlorides extended-release capsules indicated for moderate to severe Alzheimer’s dementia in patients stabilized on 10 mg donepezil (1 INDICATIONS AND USAGE).
Clinical trials have demonstrated that memantine can help improve cognitive function in individuals with moderate to severe Alzheimer's disease.
Partially supported: provided excerpts include a placeholder for “additional trial language” but do not include specific efficacy endpoints; no explicit cognitive-function improvement text is present in supplied excerpts.
Clinical trials have demonstrated that memantine can help improve global functioning in individuals with moderate to severe Alzheimer's disease.
Not supported by provided excerpts; no explicit global functioning language is included.
Clinical trials have demonstrated that memantine can help improve the ability to perform daily activities in individuals with moderate to severe Alzheimer's disease.
Not supported by provided excerpts; no explicit daily-activities efficacy language is included.
Unsupported Statements
Memantine is a prescription medication used to treat moderate to severe dementia of the Alzheimer's type.
The label indication is for the combination product “memantine and donepezil hydrochlorides extended-release capsules,” not memantine alone.
Memantine works by regulating the activity of glutamate, a neurotransmitter involved in learning and memory.
Provided label mechanism describes NMDA receptor antagonism but does not mention glutamate, learning, or memory.
In Alzheimer's disease, glutamate can overstimulate the NMDA receptor.
Not explicitly stated in provided label excerpts.
Memantine targets the NMDA receptor to help improve nerve cell function.
Mechanism is supported (NMDA antagonism) but “improve nerve cell function” is not explicitly stated in provided label excerpts.
Some patients may experience improvements in cognitive function and daily living activities within a few weeks of starting memantine.
No timeframe (“within a few weeks”) and no specific cognitive/daily living improvement language appears in provided label excerpts.
For some patients, it may take longer for memantine to show effects.
No label support for onset/timing differences in provided excerpts.
Memantine side effects can include constipation.
Constipation is not included in provided adverse reaction excerpts.
Memantine can cause back pain.
Back pain is not included in provided adverse reaction excerpts.
Memantine is usually prescribed for long-term management of moderate to severe Alzheimer's dementia.
No “long-term management” or duration language is present in provided label excerpts.
The duration of memantine treatment is determined by a healthcare professional based on the patient's individual response and disease progression.
No such individualized duration guidance appears in provided label excerpts.
Memantine is available as a generic medication.
No label support for generic availability.
Multiple companies manufacture memantine.
No label support for manufacturers.
The original patent for memantine hydrochloride expired, allowing generic versions to enter the market.
No label support for patent status.
Other treatment options for Alzheimer's disease include cholinesterase inhibitors such as rivastigmine.
Provided label excerpts do not mention rivastigmine.
Other treatment options for Alzheimer's disease include cholinesterase inhibitors such as galantamine.
Provided label excerpts do not mention galantamine.
Clinical trials have demonstrated that memantine can help improve global functioning in individuals with moderate to severe Alzheimer's disease.
No global functioning efficacy language appears in provided label excerpts.
Clinical trials have demonstrated that memantine can help improve the ability to perform daily activities in individuals with moderate to severe Alzheimer's disease.
No daily activities efficacy language appears in provided label excerpts.
Clinical studies have been crucial in establishing memantine's efficacy and safety profile.
General statement not supported with specific label language in provided excerpts.
Contradictions
Low
AI Statement
Memantine is a prescription medication used to treat moderate to severe dementia of the Alzheimer's type.
Label Reference
1 INDICATIONS AND USAGE indicates “Memantine and donepezil hydrochlorides extended-release capsules” indicated for moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg donepezil once daily.
Low
AI Statement
Memantine can cause vomiting.
Label Reference
6.1 lists vomiting among adverse reactions of donepezil hydrochloride; provided excerpts do not state vomiting as a memantine hydrochloride extended-release adverse reaction.
Important Omissions
Indication prerequisite: patients must be stabilized on 10 mg of donepezil hydrochloride once daily (for the combination product).
Importance:
Moderate
Recommended dosing (28 mg/10 mg once daily) and starting dose guidance for patients stabilized on 10 mg donepezil but not currently on memantine (7 mg/10 mg once daily in the evening).
Importance:
Moderate
Administration instructions: can be taken with/without food; may be opened and sprinkled on applesauce; do not divide/chew/crush (except described applesauce method); whole contents should be consumed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are unsupported or too general (e.g., onset timing, specific adverse effects like constipation/back pain, and individualized duration). Additionally, the indication is described as memantine alone rather than the labeled combination product with donepezil stabilization, which could mislead regarding labeled use criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the supplied label excerpts, and the indication is inaccurately framed as memantine alone instead of the labeled memantine+donepezil ER capsule indicated for patients stabilized on donepezil 10 mg.
Suggested Improvement
Limit efficacy/timing and adverse reaction lists to what is explicitly supported in the provided label excerpts; specify the labeled indication and dosing criteria for the combination product; avoid attributing donepezil-related adverse reactions to memantine unless the label excerpts support that attribution; remove or qualify statements about generic status, manufacturers, and patent expiry which are not covered in the provided labeling.